Add BrightSurf on Google Email

News tips from UCLA Health: New hope for deadly brain cancer; Mating patterns vs genetics; Do housing interventions improve health? Air pollution and neurodegenerative disease

Researchers at UCLA Health have made significant breakthroughs in understanding deadly brain cancer and the role of housing interventions. A study found a cancer vaccine to be highly effective in treating glioblastoma multiforme, a nearly lethal brain cancer. Additionally, a survey highlighted the need for increased diversity in gastro...

SourceUniversity of California - Los Angeles Health Sciences·JournalJAMA Oncology·TypeExperimental study·DateDec 1, 2022

Hunting brain cancer cells

A study published in Trends in Cancer suggests that targeting vulnerabilities in glioblastoma cancer cells, which maintain resemblance to the cells of origin, may lead to effective therapies. The research aims to identify ways to block these identity shifts and develop personalized treatments.

SourceFlinders University·JournalTrends in Cancer·TypeObservational study·DateNov 29, 2022

Brain cancer research draws support

Kevin McHugh, a Rice bioengineer, has received the Distinguished Scientist Award from The Sontag Foundation for his work on gene editing to defeat glioblastoma multiforme. His approach involves delivering gene therapy agents directly to tumor cells, aiming to improve survival and reduce side effects.

Researchers demonstrate in mice a new way to deliver medication to malignant brain tumors

Researchers demonstrate a new way to deliver medication to malignant brain tumors in mice, using a modified peptide that can penetrate the blood-brain barrier. The study shows promising results, with a 50% increase in survival rate for treated mice, and offers hope for future treatment breakthroughs.

SourceBrown University·JournalJournal of Controlled Release·TypeRandomized controlled/clinical trial·DateNov 17, 2022

Researchers identify specific alterations in the BRAF gene that may affect response to treatment and survival in adult brain cancers

The study found that BRAF alterations, particularly Class I mutations like v600E, are associated with improved overall survival in adults with glioma. However, the effectiveness of targeted therapies depends on the specific type and combination of genetic alterations driving the cancer.

SourceEuropean Organisation for Research and Treatment of Cancer·TypeRandomized controlled/clinical trial·DateOct 26, 2022

UCLA researchers identify a gene as a potential target in treatment-resistant brain cancer glioblastoma multiforme

Researchers at UCLA Jonsson Comprehensive Cancer Center and Semel Institute identified the gene P300 as a potential therapeutic target for treatment-resistant brain cancer glioblastoma multiforme. By blocking P300, tumor cells can be prevented from recovering and growing under the hostile conditions created by radiation therapy.

SourceUniversity of California - Los Angeles Health Sciences·JournalNature Communications·TypeExperimental study·DateOct 19, 2022

STTR Award to LSU Health New Orleans spin-out company to develop new class of anticancer drugs for glioblastoma

WayPath Pharma has been awarded a $225,000 Phase I Small Business Technology Transfer (STTR) award to develop new metabolic drugs targeting tumor stem cells and crossing the blood-brain barrier. The funding aims to advance treatment options for glioblastoma, a highly aggressive brain cancer with limited treatment options.

Novel T cell bispecific antibody shows potent anti-tumor activity in preclinical models of epidermal growth factor receptor variant III (EGFRvIII) mutant glioblastoma

A novel T cell bispecific antibody targeting EGFRvIII mutant glioblastoma has demonstrated potent anti-tumor activity in preclinical models. The therapy harnesses the power of the immune system to selectively target and destroy cancer cells, offering a safer treatment option for patients.

SourceVall d'Hebron Institute of Oncology·JournalMolecular Cancer Therapeutics·DateAug 2, 2022

3D model of brain tumor environment could aid personalized treatment

Virginia Tech scientists have developed a novel 3D tissue-engineered model of the glioblastoma tumor microenvironment to learn why tumors return and what treatments will be most effective. The model accounts for cell types, fluid flow, and other aspects of the actual tumor environment, allowing for easy testing of drug therapies.

SourceVirginia Tech·Journalnpj Precision Oncology·TypeComputational simulation/modeling·DateAug 1, 2022

Molecule that combines three distinct technologies against most aggressive type of brain cancer is tested

Researchers have developed a molecule that uses nanotechnology, chemotherapy and a monoclonal antibody to target glioblastoma multiforme, the most aggressive type of brain cancer. The treatment showed promise in isolated cells and animal models, with significant reductions in tumor volume and no increased toxicity.

SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalInternational Journal of Pharmaceutics·DateJun 14, 2022

Studies reveal new insights into gut microbiome impact on immunotherapy response in multiple cancers, including glioblastoma

Researchers at MD Anderson Cancer Center found distinct gut microbiome signatures associated with immunotherapy response in patients with newly diagnosed glioblastoma. The study identified a link between gut microbiome signatures and immune checkpoint blockade response in melanoma, NSCLC, and sarcoma.

Treatment which ‘switches off’ cancer cells and limits tumour growth, could make aggressive brain tumour easier to treat

Researchers have discovered a potential new treatment for glioblastoma, which targets 'kinase' proteins to limit tumour growth and improve existing chemotherapeutic drugs. This breakthrough therapy may provide hope for patients with aggressive brain tumours, offering a more effective and sustainable approach to treatment.

SourceUniversity of Sussex·JournalOncogene·DateApr 7, 2022

Houston Methodist researchers identify an immunotherapy target to combat glioblastomas

Glioblastomas, the deadliest brain cancer, have evaded immune cells by promoting immunosuppressive myeloid cells. Researchers identified S100A4 as a key molecule that can selectively target these immune suppressive cells. This discovery paves the way for new therapeutic strategies to restore antitumor action in glioblastoma patients.

SourceHouston Methodist·JournalNature Communications·TypeExperimental study·DateApr 5, 2022

Triggering cellular apoptosis by optical targeting

Researchers at Okayama University have created a new method to kill cancer cells using light-activated protein AR3, reducing the risk of adverse reactions. The approach uses green light to trigger apoptosis in targeted cells, offering a promising alternative to conventional treatments.

SourceCactus Communications·JournalJournal of the American Chemical Society·TypeExperimental study·DateMar 30, 2022

Magnetic seeds used to heat and kill cancer

Scientists at University College London have developed a novel cancer therapy using magnetic seeds guided by an MRI scanner to heat and destroy tumours. The therapy, called MINIMA, has the potential to precisely treat hard-to-reach cancers with minimal side effects.

SourceUniversity College London·JournalAdvanced Science·TypeExperimental study·DateFeb 1, 2022

TGen helps develop analysis tool, leading to more-accurate evaluation of new brain tumor treatments and individual estimates of survival

A new nomogram tool helps predict patient-level survival probabilities, accounting for sex differences in glioblastoma. The study analyzed over 1,300 patients and recommends further research on biological mechanisms underlying these differences.

SourceThe Translational Genomics Research Institute·JournalJournal of Neuro-Oncology·TypeMeta-analysis·DateDec 20, 2021

UCLA research shows why immune checkpoint blockade impedes but does not stop glioblastoma progression

A UCLA research team found that PD-1 blockade initially activates T cells and conventional dendritic cells in glioblastoma, but the immune microenvironment remains dominated by immunosuppressive cells. The study suggests that combining therapies targeting other checkpoint proteins and pathways may improve treatment outcomes.

SourceUniversity of California - Los Angeles Health Sciences·JournalNature Communications·TypeExperimental study·DateNov 29, 2021

Under arrest: Using nanofibers to stop brain tumor cells from spreading

A team of researchers from Japan has developed a platform using nanofibers to capture and control the migration of brain tumor cells, including glioblastoma multiforme. The study found that varying fiber densities can slow or speed up cell movement, leading to the creation of 'cell traps' that can restrict tumor cell growth.

SourceUniversity of Fukui·JournalACS Applied Bio Materials·TypeExperimental study·DateOct 21, 2021